Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer
- 1 May 2005
- journal article
- clinical trial
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 15 (s1) , 36-41
- https://doi.org/10.1111/j.1525-1438.2005.15355.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian CancerJNCI Journal of the National Cancer Institute, 2003
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003
- Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic DiseaseThe Oncologist, 2002
- Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer – a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study GroupAnnals of Oncology, 2001
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- Creatinine Clearance: Bedside EstimateAnnals of Internal Medicine, 1973